Which insiders are buying Anavex Life Sciences Corp. (AVXL)?

Anavex Life Sciences Corp. (NASDAQ:AVXL) marched up 46.93% compared to a 52-week low price of $2.77. The shares were last seen trading -6.44% lower, taking the closing price at $4.07 on 11/06/2017. At recent session, the prices were hovering between $4.03 and $4.44. This company shares are 268.55% off its target price of $15 and the current market capitalization stands at $167.28M. The recent change has given its price a -6.95% deficit over SMA 50 and -38.7% deficit over its 52-week high. The stock witnessed -3.33% declines, 8.82% gains and -32.5% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AVXL’s volatility during a week at 5.8% and during a month it has been found around 6.38%.

Anavex Life Sciences Corp. (AVXL) Top Holders

Institutional investors currently hold around $45 million or 24.5% in AVXL stock. Look at its top three institutional owners. Park West Asset Management Llc owns $14.37 million in Anavex Life Sciences Corp., which represents roughly 8.59% of the company’s market cap and approximately 31.93% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 1,700,827 shares of the stock are valued at $7.4 million. The third largest holder is Vanguard Group Inc, which currently holds $7.04 million worth of this stock and that ownership represents nearly 4.21% of its market capitalization.

Anavex Life Sciences Corp. 13F Filings

At the end of 06/30/2017 reporting period, 31 institutional holders increased their position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by some 984,802 shares, 19 decreased positions by 212,933 and 17 held positions by 9,032,857. That puts total institutional holdings at 10,230,592 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 115,218 shares while 7 institutional investors sold out their entire positions totaling 63,845 shares.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Insider Trades

Multiple company employees have indulged in significant insider trading. Anavex Life Sciences Corp. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Missling Christopher U has acquired 375 shares of Anavex Life Sciences Corp. (AVXL) in trading session dated Oct. 25, 2017. These shares are worth $1,646 and were traded at $4.39 each. The SEC filing shows that Missling Christopher U performed a purchase of 375 shares. The President and CEO added these shares by way of transaction on Oct. 24, 2017. The company’s shares were assimilated at $4.92 per share worth to an investment of some $1,845 on account of Missling Christopher U.

President and CEO, Missling Christopher U, purchased 375 common shares of Anavex Life Sciences Corp. (AVXL) in the open market. In a transaction dated Oct. 19, 2017, the shares were bought at an average price of $4.49, giving away a sum of $1,684. After this purchase, 1,011,500 common shares of AVXL are directly owned by the insider, with total stake valued at $4,116,805.

In the transaction dated Oct. 17, 2017, the great number of shares acquired came courtesy the President and CEO; Missling Christopher U added a total of 375 shares at an average price of $4.27, amounting to approximately $1,601. The insider now directly owns 1,011,125 shares worth $4,115,279.

Anavex Life Sciences Corp. (AVXL) Analyst Guide

Not many analysts have released their opinion on Anavex Life Sciences Corp. (NASDAQ:AVXL), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

SHARE